Cardiovascular Disease — Microbiome Signature

Overview

Cardiovascular disease (CVD) — encompassing atherosclerosis, coronary artery disease, hypertension, myocardial infarction, heart failure, and stroke — is the leading cause of death globally. The gut-heart axis has emerged as a central paradigm linking microbial metabolites to CVD pathogenesis. This signature integrates metallomic profiling from ICP-MS/MS studies, metagenome-wide association data from landmark cohorts (ACVD n=218, MetaCardis n=1,241), SCFA biology, tryptophan metabolite pathways, and emerging mycobiome evidence. The convergence of copper elevation and selenium depletion in acute events, chronic lead and cadmium exposure, TMAO overproduction by enriched Enterobacteriaceae, and SCFA depletion from butyrate-producer loss creates a multi-layered framework linking metal dyshomeostasis to cardiovascular outcomes through the gut microbiome.

Metallomic Signature

Confidence: high — supported by ICP-MS/MS case-control data ([1], n=167), NHANES epidemiological analyses ([2]), and multiple reviews.

MetalDirectionEvidence
copperElevated0.85 vs 0.73 ug/mL in AMI (p<0.01); persists 1 month post-PCI; ceruloplasmin-mediated acute phase response ([1], case-control, n=167)
seleniumDepleted90.31 vs 99.98 ng/mL in AMI (p<0.01); persistent depression at 6 months; impairs selenoprotein antioxidant defense ([1])
ironDecreased0.95 vs 1.17 ug/mL in AMI; Fe/Cu ratio significantly decreased (p<0.0001) ([1])
leadElevated (chronic)Drives hypertension and atherosclerosis via endothelial damage; reduces claudin/occludin expression ([3], animal-model)
cadmiumElevated (chronic)Endothelial damage, LDL elevation, atherosclerosis promotion; 25-30 year half-life; smoking is predominant source ([4], expert-opinion)
nickelElevated (urinary)NHANES data: 2nd and 3rd UNi quartiles show 3.57x and 3.61x CVD prevalence; inverse U-shaped dose-response ([2], cross-sectional)

The Cu/Se ratio is the most discriminating element-pair ratio for AMI. A random forest classifier incorporating Cu/Se and Fe/Cu ratios alongside traditional risk factors achieved an AUC of 0.942 (95% CI 0.889-0.970) ([1]). Essential elements exhibit ambivalent (U- or J-shaped) relationships with AMI risk, meaning both deficiency and excess are harmful.

Environmental Exposures

The metallomic signature traces to three primary exposure pathways:

  1. Smoking — the predominant determinant of plasma Cd, Al, Rb, Sr, U, V levels ([1]); smokers show 4-5x higher blood Cd ([4])
  2. Occupational/industrial exposure — Pb from legacy paint and plumbing; Ni from industrial processes; Cd from battery manufacturing and smelting
  3. Dietary exposure — Cd from phosphate fertilizer-contaminated foods; Ni from plant-based foods (legumes, nuts, whole grains); Pb from contaminated water systems
  4. Air pollution — Ni in ambient PM2.5/PM10 associated with worsening cardiovascular morbidity across 38 studies ([2])

Nutritional Immunity Response

Confidence: moderate — ceruloplasmin and selenium data are well-supported; hepcidin and calprotectin evidence is inferred from related conditions rather than CVD-specific studies.

  • Ceruloplasmin elevated — acute phase response driving copper elevation in AMI; Cu remains elevated 1 month post-PCI ([1])
  • Hepcidin elevated — iron sequestration contributing to functional iron deficiency despite adequate stores; parallels the nutritional immunity pattern seen in chronic inflammatory conditions
  • Selenoproteins depleted — persistent selenium depression at 6 months post-AMI impairs glutathione peroxidase and thioredoxin reductase antioxidant defense ([1])
  • Calprotectin/lipocalin-2 — inferred from the gut barrier disruption and Enterobacteriaceae enrichment documented in ACVD ([5]); direct CVD-specific measurements are limited

Taxonomic Analysis

Confidence: high — supported by the Jie 2017 metagenome-wide study (n=405), MetaCardis multi-omic study (n=1,241), and multiple mycobiome studies.

Enriched Taxa

enterobacteriaceae and escherichia coli are the central pathogenic taxa in the CVD signature. The Jie 2017 ACVD study found functional enrichment of TMA lyase genes (CutC/D, YeaW/X) in ACVD gut metagenomes, directly linking microbial TMAO production capacity to disease state ([5], cross-sectional, n=405). These organisms are avid iron scavengers via siderophores, thriving in the iron-dysregulated CVD gut environment.

streptococcus spp. are enriched in ACVD and share enrichment with liver cirrhosis ([5]). Oral Streptococcus species translocate to atherosclerotic plaques through inflamed periodontium, with viridans group streptococci being the most common cause of infective endocarditis ([6]).

ruminococcus gnavus — a pro-inflammatory mucin degrader enriched in ACVD ([5]).

Fungal enrichment: candida albicans increased in atherosclerosis and heart failure patients with elevated intestinal permeability ([7]). malassezia shows progressive enrichment from normotensive to pre-hypertension to hypertension, positively correlated with immunoglobulin light chains ([8]).

Depleted Taxa

roseburia, faecalibacterium prausnitzii, and clostridiales — the core butyrate-producing consortium — are depleted in ACVD ([5]). Their loss reduces SCFA-mediated cardioprotective effects including blood pressure regulation via Olfr78/GPR41, anti-atherosclerotic HDAC3 inhibition, post-MI M2 macrophage polarization, and gut barrier maintenance preventing LPS translocation ([9]; [10]).

Metal-induced depletion of these SCFA producers creates a vicious cycle: barrier disruption permits LPS translocation, driving endotoxemia and vascular inflammation, which further disrupts the gut environment ([11]).

Virulence Enzymes and Features

Confidence: moderate — TMA lyase enrichment is directly demonstrated; other enzymes are inferred from taxonomic enrichment patterns.

  • TMA lyase (CutC/CutD, YeaW/X) — functionally enriched in ACVD metagenomes; converts dietary choline, phosphatidylcholine, and L-carnitine to TMA, which is oxidized to TMAO in the liver; TMAO promotes atherosclerosis via cholesterol deposition, platelet activation, and MAPK-mediated endothelial damage ([5])
  • LPS biosynthesis enzymes — enriched in ACVD functional metagenome; LPS translocation triggers TLR4/NLR/NLRP3 inflammasome activation ([5]; [12])
  • Siderophores — produced by enriched Enterobacteriaceae; enable iron piracy in the iron-depleted CVD gut environment ([5])
  • Bacterial tryptophanase — converts tryptophan to indole, which is sulfated to indoxyl sulfate (pro-atherogenic uremic toxin); cadmium exposure upregulates indoxyl sulfate production ([13])

Ecological State

Confidence: high — supported by multiple independent lines of evidence across gut barrier, metabolite, and multi-omic studies.

The CVD gut ecosystem is characterized by:

  1. Endotoxemia — LPS translocation through a compromised gut barrier drives systemic vascular inflammation; LPS biosynthesis is functionally enriched in ACVD metagenomes ([5]). Lead and cadmium directly attack tight junction proteins (ZO-1, occludin, claudin-1) ([3])
  2. TMAO accumulation — the most established microbiome-derived CVD metabolite; high TMAO levels increase atherosclerosis risk via cholesterol deposition and platelet activation ([12])
  3. Indoxyl sulfate escalation — a uremic toxin showing escalation from dysmetabolism to IHD in the MetaCardis trajectory; promotes vascular inflammation, procoagulant state, and endothelial dysfunction ([14]; [13])
  4. SCFA depletion — reduced butyrate production from Clostridia/Roseburia/Faecalibacterium loss disrupts blood pressure regulation (Olfr78/GPR41), anti-inflammatory signaling, and gut barrier maintenance ([10])
  5. Oral-gut translocation — oral bacteria (Streptococcus, S. aureus) seed systemic circulation through inflamed periodontium, directly inoculating atherosclerotic plaques ([6])
  6. Fungal-bacterial co-dysbiosis — Candida and Malassezia enrichment compounds bacterial dysbiosis; Candida directly damages epithelial cells, amplifying metal-induced barrier disruption ([7])

The MetaCardis study identified a continuous dysmetabolism-to-IHD trajectory with 767 dysmetabolism features, 283 IHD-specific features, and progressive gene richness decline from healthy to heart failure ([14], cross-sectional, n=1,241).

Associated Conditions

CVD shares substantial signature overlap with multiple metabolic and inflammatory conditions:

[[type-2-diabetes]] (overlap score: 0.68)

The strongest overlap. Shared iron dysregulation, nickel/cadmium exposure, Enterobacteriaceae enrichment, SCFA-producer depletion, and TMAO pathway. T2D doubles CVD risk. The MetaCardis study documented a continuous dysmetabolism-to-IHD trajectory spanning both conditions ([14]).

[[obesity]] (overlap score: 0.52)

Shared metabolic inflammation, gut barrier dysfunction, Enterobacteriaceae enrichment, and Faecalibacterium/Lachnospiraceae depletion. Adipose tissue is a source of pro-inflammatory cytokines (TNF-alpha, IL-6) that drive atherosclerosis. Cadmium functions as an environmental obesogen ([11]).

[[chronic-kidney-disease]] (overlap score: 0.48)

Shared uremic toxin accumulation (indoxyl sulfate, p-cresol sulfate), lead/cadmium exposure, and Enterobacteriaceae enrichment. CKD accelerates atherosclerosis. Gut mycobiome alterations overlap in HTN+CKD patients ([15]).

[[depression]] (overlap score: 0.42)

Shared gut-brain axis disruption, tryptophan pathway shifts toward pro-inflammatory kynurenine, SCFA depletion, and butyrate-producer loss. CVD patients have 2-3x higher depression rates. Depression independently increases CVD mortality.

Open Questions

  1. Causal direction of Cu/Se dysregulation — Is the copper elevation / selenium depletion a cause or consequence of AMI? Prospective studies with pre-event metallomic profiling are needed.
  2. Drug confounding — Polypharmacy (fondaparinux, acarbose, metoprolol, atorvastatin) was the major confounding factor in the Jie 2017 study ([5]). How much of the observed dysbiosis is drug-induced vs. disease-driven?
  3. Nickel dose-response — The inverse U-shaped relationship between urinary nickel and CVD prevalence needs clarification with prospective data ([2]).
  4. Mycobiome therapeutic targets — Can antifungal interventions targeting Candida/Malassezia reduce CVD risk, or is fungal enrichment a downstream consequence?
  5. TMAO threshold — What plasma TMAO level constitutes clinically actionable cardiovascular risk, and can TMA lyase inhibitors serve as CVD therapeutics?
  6. Multi-site dysbiosis — Does oral-gut co-dysbiosis have a synergistic effect on CVD risk beyond either site alone?

Karen's Brain Primitives Active

  • Primitive 1: Metals as Selective Pressures — Copper elevation and Pb/Cd exposure select for metal-tolerant Enterobacteriaceae while eliminating metal-sensitive butyrate producers (Roseburia, Faecalibacterium, Clostridiales)
  • Primitive 2: Nutritional Immunity as Interpretive Constraint — Iron depletion in AMI may reflect hepcidin-mediated host defense rather than true deficiency; selenium depletion reflects selenoprotein consumption during oxidative stress
  • Primitive 4: Microbial Metal Dependencies as Achilles' Heels — Enterobacteriaceae depend on iron via siderophores; restricting iron availability could reduce TMA lyase-carrying pathogen load
  • Primitive 5: Two-Sided Ecological Engineering — Suppress TMAO-producing Enterobacteriaceae AND restore SCFA-producing Roseburia/Faecalibacterium to re-establish the Olfr78/GPR41 blood pressure buffering system
  • Primitive 6: Interkingdom Relationships and Functional Shielding — Candida/Malassezia enrichment compounds bacterial dysbiosis and barrier disruption in CVD
  • Primitive 8: Siderophore Competition and Iron Ecology — Enterobacteriaceae siderophore production enables iron piracy in the CVD gut; competitive exclusion strategies may be viable
  • Primitive 9: Oxygen State as Ecological Determinant — Butyrate-producer depletion may shift the colonic environment toward higher oxygen tension, further favoring facultative anaerobes like E. coli

References (17)

  1. . lim 2023 plasma metallomics ami
  2. . liu 2025 cardiometabolic nickel
  3. . ghosh 2023 heavy metals gut barrier integrity
  4. . rasin 2025 cadmium exposure health review
  5. . jie 2017 gut microbiome acvd
  6. . tonelli 2023 oral microbiome cvd pathophysiology
  7. . wei 2025 gut mycobiome cardiometabolic disease
  8. . zou 2022 mycobiome dysbiosis hypertension light chains
  9. . lu 2022 scfas cardiovascular metabolic disease
  10. . chambers 2018 scfa metabolic cardiovascular health
  11. . pendergrass 2026 heavy metals obesity epidemic
  12. . wang 2022 gut microbiota health cvd review
  13. . paeslack 2022 tryptophan metabolites vascular inflammation cvd
  14. . fromentin 2022 microbiome metabolome cardiometabolic spectrum
  15. . qiu 2023 gut mycobiome hypertension ckd
  16. . almeida 2023 gut microbiota cardiovascular axis
  17. . zhu 2024 toxic essential metals gut microbiota

Related Articles